| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
84.83(B) |
| Last
Volume: |
4,830,404 |
Avg
Vol: |
8,731,484 |
| 52
Week Range: |
$64.58 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,230 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$890,904 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
3 |
5 |
9 |
14 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cogan John Francis |
Director |
• • – |
2020-04-27 |
4 |
AS |
$79.90 |
$192,799 |
D/D |
(2,413) |
54,860 |
|
-17% |
|
| Cogan John Francis |
Director |
• • – |
2020-04-27 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2020-04-20 |
4 |
AS |
$83.00 |
$200,279 |
D/D |
(2,413) |
54,860 |
|
-20% |
|
| Cogan John Francis |
Director |
• • – |
2020-04-20 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2020-04-13 |
4 |
AS |
$75.90 |
$183,147 |
D/D |
(2,413) |
54,860 |
|
-10% |
|
| Cogan John Francis |
Director |
• • – |
2020-04-13 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2020-04-06 |
4 |
AS |
$79.52 |
$191,882 |
D/D |
(2,413) |
54,860 |
|
-12% |
|
| Cogan John Francis |
Director |
• • – |
2020-04-06 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2020-03-30 |
4 |
AS |
$75.35 |
$181,820 |
D/D |
(2,413) |
54,860 |
|
-6% |
|
| Cogan John Francis |
Director |
• • – |
2020-03-30 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2020-03-23 |
4 |
AS |
$75.27 |
$181,627 |
D/D |
(2,413) |
54,860 |
|
-4% |
|
| Cogan John Francis |
Director |
• • – |
2020-03-23 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2020-03-16 |
4 |
AS |
$67.26 |
$162,298 |
D/D |
(2,413) |
54,860 |
|
7% |
|
| Cogan John Francis |
Director |
• • – |
2020-03-16 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2020-03-10 |
4 |
AS |
$75.55 |
$222,873 |
D/D |
(2,950) |
14,644 |
|
8% |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2020-03-10 |
4 |
OE |
$24.30 |
$71,670 |
D/D |
2,950 |
17,594 |
|
- |
|
| Dickinson Andrew D |
EVP, Chief Financial Officer |
• • – |
2020-03-10 |
4 |
D |
$72.34 |
$25,753 |
D/D |
(356) |
11,400 |
|
- |
|
| Dickinson Andrew D |
EVP, Chief Financial Officer |
• • – |
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
769 |
11,756 |
|
- |
|
| Wilfong Diane E |
SVP, Controller & CAO |
• • – |
2020-03-10 |
4 |
D |
$72.34 |
$37,906 |
D/D |
(524) |
12,199 |
|
- |
|
| Wilfong Diane E |
SVP, Controller & CAO |
• • – |
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,865 |
12,723 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2020-03-09 |
4 |
AS |
$77.97 |
$188,142 |
D/D |
(2,413) |
54,860 |
|
2% |
|
| Cogan John Francis |
Director |
• • – |
2020-03-09 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2020-03-02 |
4 |
AS |
$70.83 |
$740,014 |
D/D |
(10,441) |
14,644 |
|
1% |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2020-03-01 |
4 |
D |
$69.36 |
$1,797,950 |
D/D |
(25,922) |
47,570 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
54,288 |
73,492 |
|
- |
|
1105 Records found
|
|
Page 13 of 45 |
|
|
0.85 (1.27%) 
